| __timestamp | Geron Corporation | MiMedx Group, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8901000 | 12665000 |
| Thursday, January 1, 2015 | 9574000 | 20202000 |
| Friday, January 1, 2016 | 14695000 | 32407000 |
| Sunday, January 1, 2017 | 8437000 | 35219000 |
| Monday, January 1, 2018 | 12723000 | 36386000 |
| Tuesday, January 1, 2019 | 51272000 | 43081000 |
| Wednesday, January 1, 2020 | 50052000 | 39330000 |
| Friday, January 1, 2021 | 783000 | 43283000 |
| Saturday, January 1, 2022 | 868000 | 48316000 |
| Sunday, January 1, 2023 | 123740000 | 54634000 |
Unlocking the unknown
In the ever-evolving landscape of biotechnology, cost efficiency remains a pivotal factor for success. This analysis delves into the cost of revenue trends for Geron Corporation and MiMedx Group, Inc. from 2014 to 2023. Over this period, MiMedx Group consistently demonstrated a more stable cost structure, with costs peaking at approximately $54.6 million in 2023, marking a 330% increase from 2014. In contrast, Geron Corporation exhibited significant volatility, with costs surging by over 1,300% in 2023 compared to 2014. Notably, Geron's cost efficiency plummeted in 2021 and 2022, with costs dropping to under $1 million, before a dramatic rebound in 2023. This fluctuation highlights the challenges and dynamic nature of managing costs in the biotech sector. As investors and stakeholders seek sustainable growth, understanding these trends is crucial for strategic decision-making.
Cost of Revenue Trends: Novo Nordisk A/S vs MiMedx Group, Inc.
Comparing Cost of Revenue Efficiency: GSK plc vs Geron Corporation
Takeda Pharmaceutical Company Limited vs Geron Corporation: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Geron Corporation
Analyzing Cost of Revenue: Dr. Reddy's Laboratories Limited and MiMedx Group, Inc.
Walgreens Boots Alliance, Inc. vs Geron Corporation: Efficiency in Cost of Revenue Explored
Vericel Corporation vs Geron Corporation: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Ligand Pharmaceuticals Incorporated and MiMedx Group, Inc.'s Expenses
Cost of Revenue Comparison: Geron Corporation vs Travere Therapeutics, Inc.
Cost of Revenue Comparison: Wave Life Sciences Ltd. vs MiMedx Group, Inc.
Comparing Cost of Revenue Efficiency: Celldex Therapeutics, Inc. vs MiMedx Group, Inc.
Xencor, Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored